| dbo:abstract | - Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that would be acquiring Sunosi from Jazz Pharmaceuticals In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). (en)
- Jazz Pharmaceuticals est une entreprise pharmaceutique dont le siège social est en Irlande. (fr)
- Jazz Pharmaceuticals — международная фармацевтическая компания. Штаб-квартира расположена в Дублине (Ирландия), офисы в США находятся в Калифорнии (Пало-Алто и Карлсбад) и в Пенсильвании (Филадельфия). Специализируется на препаратах на основе оксибутират натрия (Xywav и Xyrem). (ru)
|
| dbo:assets | |
| dbo:equity | |
| dbo:industry | |
| dbo:keyPerson | |
| dbo:location | |
| dbo:netIncome | |
| dbo:numberOfEmployees | - 1210 (xsd:nonNegativeInteger)
|
| dbo:operatingIncome | |
| dbo:predecessor | |
| dbo:product | |
| dbo:revenue | |
| dbo:thumbnail | |
| dbo:wikiPageID | |
| dbo:wikiPageLength | - 13350 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID | |
| dbo:wikiPageWikiLink | |
| dbp:areaServed | |
| dbp:assets | |
| dbp:brands | |
| dbp:equity | |
| dbp:founded | |
| dbp:industry | |
| dbp:keyPeople | |
| dbp:location | - Waterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland (en)
|
| dbp:logo | - File:Jazz Pharmaceuticals logo.png (en)
|
| dbp:name | - Jazz Pharmaceuticals plc (en)
|
| dbp:netIncome | |
| dbp:numEmployees | |
| dbp:operatingIncome | |
| dbp:predecessor | - Jazz Pharmaceuticals, Inc. (en)
|
| dbp:products | |
| dbp:revenue | |
| dbp:type | |
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type | |
| rdfs:comment | - Jazz Pharmaceuticals est une entreprise pharmaceutique dont le siège social est en Irlande. (fr)
- Jazz Pharmaceuticals — международная фармацевтическая компания. Штаб-квартира расположена в Дублине (Ирландия), офисы в США находятся в Калифорнии (Пало-Алто и Карлсбад) и в Пенсильвании (Филадельфия). Специализируется на препаратах на основе оксибутират натрия (Xywav и Xyrem). (ru)
- Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that would be acquiring Sunosi from Jazz Pharmaceuticals (en)
|
| rdfs:label | - Jazz Pharmaceuticals (fr)
- Jazz Pharmaceuticals (en)
- Jazz Pharmaceuticals (ru)
|
| owl:sameAs | |
| skos:closeMatch | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| foaf:name | - Jazz Pharmaceuticals plc (en)
|
| isdbo:parentCompany of | |
| isdbo:wikiPageRedirects of | |
| isdbo:wikiPageWikiLink of | |
| isdbp:parent of | |
| isfoaf:primaryTopic of | |
